(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of 5.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Sutro Biopharma's revenue in 2025 is $66,434,000.On average, 6 Wall Street analysts forecast STRO's revenue for 2025 to be $7,693,839,122, with the lowest STRO revenue forecast at $5,380,188,951, and the highest STRO revenue forecast at $9,387,036,106. On average, 5 Wall Street analysts forecast STRO's revenue for 2026 to be $5,807,056,689, with the lowest STRO revenue forecast at $844,613,650, and the highest STRO revenue forecast at $9,856,641,296.
In 2027, STRO is forecast to generate $7,404,390,024 in revenue, with the lowest revenue forecast at $5,380,188,951 and the highest revenue forecast at $10,349,895,667.